BioMarin Scores Patent Board Win; Sarepta To Appeal
This article was originally published in Scrip
Executive Summary
Shares of BioMarin Pharmaceutical Inc. leaped more than 13% on Sept. 30 after the firm scored a win at the Patent Trial and Appeal Board (PTAB) of the U.S. Patent & Trademark Office (US PTO) in a patent interference dispute with Sarepta Therapeutics Inc. involving methods of use claims for the firms' respective experimental Duchenne muscular dystrophy (DMD) drugs drisapersen and eteplirsen.
